Geoffrey Porges
Stock Analyst at Leerink Partners
(1.50)
# 3,423
Out of 5,182 analysts
114
Total ratings
47.37%
Success rate
-1.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Maintains: Outperform | $36 → $49 | $24.75 | +97.98% | 9 | Mar 2, 2026 | |
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $26.81 | +108.88% | 10 | Dec 15, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $748.99 | +13.49% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $63.76 | -24.72% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $343.21 | -37.06% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $198.96 | -32.15% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $27.94 | -60.62% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $129.75 | -42.20% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $46.19 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $16.74 | -40.26% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $430.58 | -59.36% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $27.40 | +206.57% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $54.98 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $7.27 | +739.06% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $183.48 | - | 8 | Mar 16, 2017 |
Arcus Biosciences
Mar 2, 2026
Maintains: Outperform
Price Target: $36 → $49
Current: $24.75
Upside: +97.98%
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $26.81
Upside: +108.88%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $748.99
Upside: +13.49%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $63.76
Upside: -24.72%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $343.21
Upside: -37.06%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $198.96
Upside: -32.15%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $27.94
Upside: -60.62%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $129.75
Upside: -42.20%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $46.19
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $16.74
Upside: -40.26%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $430.58
Upside: -59.36%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $27.40
Upside: +206.57%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $54.98
Upside: -
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $7.27
Upside: +739.06%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $183.48
Upside: -